Abbott India Limited (NSE: ABBOTINDIA)
India
· Delayed Price · Currency is INR | Market Cap | 604.80B |
| Revenue (ttm) | 60.66B |
| Net Income (ttm) | 12.85B |
| Shares Out | n/a |
| EPS (ttm) | 604.57 |
| PE Ratio | 47.08 |
| Forward PE | n/a |
| Dividend | 410.00 (1.46%) |
| Ex-Dividend Date | Jul 19, 2024 |
| Volume | 5,768 |
| Open | 28,581 |
| Previous Close | 28,559 |
| Day's Range | 28,096 - 28,648 |
| 52-Week Range | 22,239 - 30,521 |
| Beta | 0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 7, 2025 |
About Abbott India
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women’s health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a... [Read more]
Financial Performance
In 2023, Abbott India's revenue was 58.49 billion, an increase of 9.35% compared to the previous year's 53.49 billion. Earnings were 12.01 billion, an increase of 26.52%.
Financial StatementsNews
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Abbott India launches 14-Valent Pneumococcal Conjugate vaccine offering broad protection for children
The PneumoShield 14 vaccine protects against 14 different strains of pneumococcal bacteria, exceeding the coverage of PCV-10 and PCV-13 vaccines currently available in India.
Abbott India shares fall nearly 4% following Q2 results
Abbott India reported its financial performance for the second quarter of FY25, showcasing solid growth in both revenue and net profit compared to the same period last year. However, the positive resu...
Abbott India Q2 FY25 Results: Revenue up 9.3% YoY to ₹1,632.67 crore, Net Profit rises 14.6% YoY
Abbott India Ltd. reported its financial results for the second quarter of FY25, showing strong growth in both revenue and net profit compared to the same period last year. Financial Highlights Revenu...
Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%
As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...
Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today
JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.
Abbott India partners with Takeda Pharmaceuticals to launch Vonefi
Abbott India Limited has announced the signing of a non-exclusive patent license agreement with Takeda Pharmaceuticals Company Limited to market and distribute Vonoprazan in India under the brand name...